Validation of the L-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists

Brain Research Bulletin

Volumn 68, Issue 1-2, 2005, Pages 16-23

  Monville, Christelle ^a   Torres, Eduardo M ^a   Dunnett, Stephen B ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Abnormal movements; c fos; Met enkephalin; Parkinson's disease

Indexed keywords

2,10,11 TRIHYDROXY N PROPYLNORAPORPHINEHYDROBROMIDE; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 7 HYDROXYDIPROPYLAMINOTETRALIN; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA METHYL ESTER; NAFADOTRIDE; OXIDOPAMINE; RACLOPRIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONVALESCENCE; DRUG EFFECT; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; DYSKINESIA; FEMALE; FORELIMB; HUMAN; NERVE GRAFT; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; RATING SCALE; REPRODUCIBILITY; VALIDATION PROCESS;

ANIMALS; ANTIPARKINSON AGENTS; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DYSKINESIA, DRUG-INDUCED; ENKEPHALIN, METHIONINE; FEMALE; LEVODOPA; OXIDOPAMINE; PARKINSON DISEASE; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE; REPRODUCIBILITY OF RESULTS; SYMPATHOLYTICS;

EID: 28144463965     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2004.10.011     Document Type: Article

References (40)

1. G.E. Alexander, and M.D. Crutcher Functional architecture of basal ganglia circuits: neural substrates of parallel processing Trends Neurosci. 13 1990 266 271
2. P.J. Bedard, T. Di Paolo, P. Falardeau, and R. Boucher Chronic treatment with l-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding Brain Res. 379 1986 294 299
3. E. Bezard, J.M. Brotchie, and C.E. Gross Pathophysiology of levodopa-induced dyskinesia: potential for new therapies Nat. Rev. Neurosci. 2 2001 577 588
4. E. Bezard, P. Ravenscroft, C.E. Gross, A.R. Crossman, and J.M. Brotchie Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys Neurobiol. Dis. 8 2001 343 350
5. W. Birkmayer, and O. Hornykiewicz The l-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia Wien. Klin. Wochenschr. 73 1961 787 788
6. P. Blanchet, P.J. Bedard, D.R. Britton, and J.W. Kebabian Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys J. Pharmacol. Exp. Ther. 267 1993 275 279
7. P.J. Blanchet, F. Calon, J.C. Martel, P.J. Bedard, T. Di Paolo, R.R. Walters, and M.F. Piercey Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys J. Pharmacol. Exp. Ther. 272 1995 854 859
8. R. Bordet, S. Ridray, S. Carboni, J. Diaz, P. Sokoloff, and J.C. Schwartz Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa Proc. Natl. Acad. Sci. U.S.A. 94 1997 3363 3367
9. R. Bordet, S. Ridray, J.C. Schwartz, and P. Sokoloff Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats Eur. J. Neurosci. 12 2000 2117 2123
10. D.J. Brooks The early diagnosis of Parkinson's disease Ann. Neurol. 44 1998 10 18
11. A. Carlsson, M. Lindqvist, and T. Magnusson 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists Nature 180 1957 1200
12. M.A. Cenci, C.S. Lee, and A. Bjorklund l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA Eur. J. Neurosci. 10 1998 2694 2706
13. M.R. DeLong Primate models of movement disorders of basal ganglia origin Trends Neurosci. 13 1990 281 285
14. R.C. Duvoisin Variations in the "on-off" phenomenon Adv. Neurol. 5 1974 339 340
15. S. Fahn "On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine Neurology 24 1974 431 441
16. P. Falardeau, S. Bouchard, P.J. Bedard, R. Boucher, and T. Di Paolo Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys Eur. J. Pharmacol. 150 1988 59 66
17. J.M. Fearnley, and A.J. Lees Ageing Parkinson's disease: substantia nigra regional selectivity Brain 114 Pt. 5 1991 2283 2301
18. C.R. Gerfen, T.M. Engber, L.C. Mahan, Z. Susel, T.N. Chase, F.J. Monsma Jr., and D.R. Sibley D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons Science 250 1990 1429 1432
19. C.R. Gerfen, J.F. McGinty, and W.S. Young III Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis J. Neurosci. 11 1991 1016 1031
20. B. Gomez-Mancilla, and P.J. Bedard Effect of D1 and D2 agonists and antagonists on dyskinesia produced by l-dopa in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-treated monkeys J. Pharmacol. Exp. Ther. 259 1991 409 413
21. R. Grondin, M. Goulet, T. Di Paolo, and P.J. Bedard Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates Brain Res. 735 1996 298 306
22. C.E. Gross, P. Ravenscroft, S. Dovero, M. Jaber, B. Bioulac, and E. Bezard Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice J. Neurochem. 84 2003 1246 1255
23. B. Henry, S.H. Fox, A.R. Crossman, and J.M. Brotchie Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease Exp. Neurol. 171 2001 139 146
24. R. Klintenberg, P. Svenningsson, L. Gunne, and P.E. Andren Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism J. Neural Transm. 109 2002 1295 1307
25. J.W. Langston, and P. Ballard Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease Can. J. Neurol. Sci. 11 1984 160 165
26. C. Le Moine, and B. Bloch D1 and D2 dopamine receptor gene expression in the rat striatum: sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum J. Comp. Neurol. 355 1995 418 426
27. E.C. Maratos, M.J. Jackson, R.K. Pearce, C. Cannizzaro, and P. Jenner Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than l-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus) Exp. Neurol. 179 2003 90 102
28. E.C. Maratos, M.J. Jackson, R.K. Pearce, and P. Jenner Antiparkinsonian activity and dyskinesia risk of ropinirole and l-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus) Mov. Disord. 16 2001 631 641
29. C.D. Marsden, and J.D. Parkes "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy Lancet 1 1976 292 296
30. E.G. Meloni, and M. Davis Enhancement of the acoustic startle response by dopamine agonists after 6-hydroxydopamine lesions of the substantia nigra pars compacta: corresponding changes in c-Fos expression in the caudate-putamen Brain Res. 879 2000 93 104
31. L.K. Nisenbaum, S.T. Kitai, W.R. Crowley, and C.R. Gerfen Temporal dissociation between changes in striatal enkephalin and substance P messenger RNAs following striatal dopamine depletion Neuroscience 60 1994 927 937
32. J.G. Nutt Levodopa-induced dyskinesia: review, observations, and speculations Neurology 40 1990 340 345
33. R.K. Pearce, T. Banerji, P. Jenner, and C.D. Marsden De novo administration of ropinirole and bromocriptine induces less dyskinesia than l-dopa in the MPTP-treated marmoset Mov. Disord. 13 1998 234 241
34. O. Rascol, J.G. Nutt, O. Blin, C.G. Goetz, J.M. Trugman, C. Soubrouillard, J.H. Carter, L.J. Currie, N. Fabre, C. Thalamas, W.W. Giardina, and S. Wright Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease Arch. Neurol. 58 2001 249 254
35. T. Schallert, S.M. Fleming, J.L. Leasure, J.L. Tillerson, and S.T. Bland CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury Neuropharmacology 39 2000 777 787
36. K. Steece-Collier, T.J. Collier, P.D. Danielson, R. Kurlan, D.M. Yurek, and J.R. Sladek Jr. Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in parkinsonian rats Mov. Disord. 18 2003 1442 1454
37. P. Svenningsson, L. Gunne, and P.E. Andren l-DOPA produces strong induction of c-fos messenger RNA in dopamine-denervated cortical and striatal areas of the common marmoset Neuroscience 99 2000 457 468
38. U. Ungerstedt, and G.W. Arbuthnott Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system Brain Res. 24 1970 485 493
39. P. Vernier, J.F. Julien, P. Rataboul, O. Fourrier, C. Feuerstein, and J. Mallet Similar time course changes in striatal levels of glutamic acid decarboxylase and proenkephalin mRNA following dopaminergic deafferentation in the rat J. Neurochem. 51 1988 1375 1380
40. C. Winkler, D. Kirik, A. Bjorklund, and M.A. Cenci l-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function Neurobiol. Dis. 10 2002 165 186